Reliance Life Sciences Private Limited FDA Record
- Latest inspection OAI · Feb 27, 2026
- Last warning letter 2026
Reliance Life Sciences Private Limited has 4 FDA recalls, 8 inspections, 0 510(k) clearances and 1 compliance action on record. FDA has issued 1 warning letter to Reliance Life Sciences Private Limited, the most recent on Aug 18, 2026. FDA has published 1 Form 483 for Reliance Life Sciences Private Limited.
- Latest recall
- D-0671-2026 · Class II · Jun 24, 2026
- Latest inspection
- Feb 27, 2026 · OAI
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 4 | Nov 11, 2026 (checked Nov 15, 2026, unchanged) | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 8 | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions | 1 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Reliance Life Sciences Private Limited: FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 1 | 1 | 1 | 4 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 1 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 1 | 0 | 0 | 0 | 0 |
| 2018 | 2 | 0 | 0 | 0 | 0 |
| 2017 | 1 | 0 | 0 | 0 | 0 |
Reviewing Reliance Life Sciences Private Limited as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Reliance Life Sciences Private Limited yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Reliance Life Sciences Private Limited FDA Warning Letters
| Issued | Subject | Issuing office | Close-out letter |
|---|---|---|---|
| Aug 18, 2026 · Letter on fda.gov | CGMP/Finished Pharmaceuticals/Adulterated | Center for Drug Evaluation and Research (CDER) |
Reliance Life Sciences Private Limited Form 483s
| Date | Document | FEI |
|---|---|---|
| Feb 27, 2026 · Document on fda.gov | 483 | 3009510975 |
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0671-2026 | Class II | Pemetrexed for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For intravenous use only… | Jun 24, 2026 |
| D-0673-2026 | Class II | Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous… | Jun 24, 2026 |
| D-0672-2026 | Class II | Pemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For intravenous use only… | Jun 24, 2026 |
| D-0674-2026 | Class II | Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and… | Jun 24, 2026 |
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Feb 27, 2026 | Navi Mumbai, India | Drugs | Official Action Indicated (OAI) | 3009510975 |
| Apr 15, 2022 | Navi Mumbai, India | Drugs | No Action Indicated (NAI) | 3009510975 |
| Nov 22, 2019 | Navi Mumbai, India | Drugs | Voluntary Action Indicated (VAI) | 3009510975 |
| Oct 16, 2018 | Navi Mumbai, India | Drugs | Voluntary Action Indicated (VAI) | 3009510975 |
| Jan 25, 2018 | Navi Mumbai, India | Drugs | No Action Indicated (NAI) | 3009510975 |
| Dec 13, 2017 | Navi Mumbai, India | Drugs | Voluntary Action Indicated (VAI) | 3009510975 |
| Aug 14, 2015 | Navi Mumbai, India | Drugs | Voluntary Action Indicated (VAI) | 3009510975 |
| Aug 23, 2013 | Navi Mumbai, India | Drugs | Official Action Indicated (OAI) | 3009510975 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
Compliance Actions
FDA's compliance actions data lists 1 compliance action under Reliance Life Sciences Private Limited: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 3009510975 | Navi Mumbai, India | 8 | Feb 27, 2026 |
Reliance Life Sciences Private Limited and the FDA: common questions
Has Reliance Life Sciences Private Limited received an FDA warning letter?
Yes. FDA has issued 1 warning letter to Reliance Life Sciences Private Limited. The most recent is dated Aug 18, 2026, with the subject "CGMP/Finished Pharmaceuticals/Adulterated".
Has Reliance Life Sciences Private Limited received an FDA Form 483?
FDA has published 1 Form 483 for Reliance Life Sciences Private Limited in its reading room, the most recent dated Feb 27, 2026. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect Reliance Life Sciences Private Limited?
The most recent FDA inspection on file ended Feb 27, 2026 at Navi Mumbai, India and was classified OAI. FDA has 8 inspections of Reliance Life Sciences Private Limited on file, 2 of them classified OAI (official action indicated).
Has Reliance Life Sciences Private Limited had an FDA recall?
Yes. Reliance Life Sciences Private Limited has 4 FDA recalls on record. The most recent started Jun 24, 2026.
Need more than this page shows? Ask about Reliance Life Sciences Private Limited in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.